Published in J Clin Endocrinol Metab on October 02, 2007
Reactivation of the silenced thyroid hormone receptor β gene expression delays thyroid tumor progression. Endocrinology (2012) 1.00
Thyroid hormone receptors and cancer. Biochim Biophys Acta (2012) 0.99
Synergistic signaling of KRAS and thyroid hormone receptor β mutants promotes undifferentiated thyroid cancer through MYC up-regulation. Neoplasia (2014) 0.96
Inhibition of estrogen-dependent tumorigenesis by the thyroid hormone receptor β in xenograft models. Am J Cancer Res (2013) 0.82
Inhibition of tumorigenesis by the thyroid hormone receptor β in xenograft models. Thyroid (2013) 0.82
Epigenetic regulation of thyroid hormone receptor beta in renal cancer. PLoS One (2014) 0.82
Thyroid hormone receptor β suppresses SV40-mediated tumorigenesis via novel nongenomic actions. Am J Cancer Res (2012) 0.80
Oncogenic mutations of thyroid hormone receptor β. Oncotarget (2015) 0.80
Src-dependent phosphorylation at Y406 on the thyroid hormone receptor β confers the tumor suppressor activity. Oncotarget (2014) 0.78
Common genetic variants in pituitary-thyroid axis genes and the risk of differentiated thyroid cancer. Endocr Connect (2012) 0.76
Thyroid Hormone Receptor-β (TRβ) Mediates Runt-Related Transcription Factor 2 (Runx2) Expression in Thyroid Cancer Cells: A Novel Signaling Pathway in Thyroid Cancer. Endocrinology (2016) 0.75
BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst (2003) 6.20
Integrated soil-crop system management for food security. Proc Natl Acad Sci U S A (2011) 4.14
BRAF mutation testing of thyroid fine-needle aspiration biopsy specimens for preoperative risk stratification in papillary thyroid cancer. J Clin Oncol (2009) 3.02
Highly prevalent genetic alterations in receptor tyrosine kinases and phosphatidylinositol 3-kinase/akt and mitogen-activated protein kinase pathways in anaplastic and follicular thyroid cancers. J Clin Endocrinol Metab (2008) 2.89
Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocr Relat Cancer (2013) 2.69
Genetic alterations and their relationship in the phosphatidylinositol 3-kinase/Akt pathway in thyroid cancer. Clin Cancer Res (2007) 2.61
Somatic mutation and gain of copy number of PIK3CA in human breast cancer. Breast Cancer Res (2005) 2.20
The Akt-specific inhibitor MK2206 selectively inhibits thyroid cancer cells harboring mutations that can activate the PI3K/Akt pathway. J Clin Endocrinol Metab (2011) 2.06
The BRAF(V600E) causes widespread alterations in gene methylation in the genome of melanoma cells. Cell Cycle (2012) 1.98
Potent inhibition of thyroid cancer cells by the MEK inhibitor PD0325901 and its potentiation by suppression of the PI3K and NF-kappaB pathways. Thyroid (2008) 1.93
Anaplastic thyroid cancers harbor novel oncogenic mutations of the ALK gene. Cancer Res (2011) 1.85
Identification of RASAL1 as a major tumor suppressor gene in thyroid cancer. J Natl Cancer Inst (2013) 1.78
BRAF mutation in papillary thyroid cancer and its value in tailoring initial treatment: a systematic review and meta-analysis. Medicine (Baltimore) (2012) 1.77
Tumor-specific changes in mtDNA content in human cancer. Int J Cancer (2005) 1.70
Selective growth inhibition in BRAF mutant thyroid cancer by the mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244. J Clin Endocrinol Metab (2007) 1.66
Gene methylation in gastric cancer. Clin Chim Acta (2013) 1.63
Association of aberrant methylation of tumor suppressor genes with tumor aggressiveness and BRAF mutation in papillary thyroid cancer. Int J Cancer (2006) 1.56
Association of high iodine intake with the T1799A BRAF mutation in papillary thyroid cancer. J Clin Endocrinol Metab (2009) 1.55
Highly prevalent TERT promoter mutations in bladder cancer and glioblastoma. Cell Cycle (2013) 1.52
TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. J Clin Endocrinol Metab (2014) 1.52
Uncommon mutation, but common amplifications, of the PIK3CA gene in thyroid tumors. J Clin Endocrinol Metab (2005) 1.51
OPCML is a broad tumor suppressor for multiple carcinomas and lymphomas with frequently epigenetic inactivation. PLoS One (2008) 1.47
High prevalence and mutual exclusivity of genetic alterations in the phosphatidylinositol-3-kinase/akt pathway in thyroid tumors. J Clin Endocrinol Metab (2007) 1.47
DeltaNp63alpha up-regulates the Hsp70 gene in human cancer. Cancer Res (2005) 1.44
Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer (2012) 1.39
Association of PTEN gene methylation with genetic alterations in the phosphatidylinositol 3-kinase/AKT signaling pathway in thyroid tumors. Cancer (2008) 1.39
Suppression of BRAF/MEK/MAP kinase pathway restores expression of iodide-metabolizing genes in thyroid cells expressing the V600E BRAF mutant. Clin Cancer Res (2007) 1.39
Genetic alterations in the phosphoinositide 3-kinase/Akt signaling pathway confer sensitivity of thyroid cancer cells to therapeutic targeting of Akt and mammalian target of rapamycin. Cancer Res (2009) 1.31
Identification and functional characterization of isocitrate dehydrogenase 1 (IDH1) mutations in thyroid cancer. Biochem Biophys Res Commun (2010) 1.31
Synthesis and characterization of biocompatible Fe3O4 nanoparticles. J Biomed Mater Res A (2007) 1.28
Highly frequent promoter methylation and PIK3CA amplification in non-small cell lung cancer (NSCLC). BMC Cancer (2011) 1.19
Inhibitory effects of the mitogen-activated protein kinase kinase inhibitor CI-1040 on the proliferation and tumor growth of thyroid cancer cells with BRAF or RAS mutations. J Clin Endocrinol Metab (2007) 1.19
MEK1 mutations, but not ERK2 mutations, occur in melanomas and colon carcinomas, but none in thyroid carcinomas. Cell Cycle (2009) 1.17
Chronic mild stress impairs cognition in mice: from brain homeostasis to behavior. Life Sci (2008) 1.16
Genome-wide alterations in gene methylation by the BRAF V600E mutation in papillary thyroid cancer cells. Endocr Relat Cancer (2011) 1.16
BRAF mutation-selective inhibition of thyroid cancer cells by the novel MEK inhibitor RDEA119 and genetic-potentiated synergism with the mTOR inhibitor temsirolimus. Int J Cancer (2010) 1.14
Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer. Cell Cycle (2007) 1.14
BRAF V600E maintains proliferation, transformation, and tumorigenicity of BRAF-mutant papillary thyroid cancer cells. J Clin Endocrinol Metab (2007) 1.12
Prognostic significance of aberrant gene methylation in gastric cancer. Am J Cancer Res (2011) 1.10
The BRAFT1799A mutation confers sensitivity of thyroid cancer cells to the BRAFV600E inhibitor PLX4032 (RG7204). Biochem Biophys Res Commun (2010) 1.08
Helicobacter pylori vacA genotypes and cagA status and their relationship to associated diseases. World J Gastroenterol (2000) 1.06
Induction of thyroid gene expression and radioiodine uptake in thyroid cancer cells by targeting major signaling pathways. J Clin Endocrinol Metab (2009) 1.06
MiR-145 inhibits oral squamous cell carcinoma (OSCC) cell growth by targeting c-Myc and Cdk6. Cancer Cell Int (2013) 1.05
High prevalence and possible de novo formation of BRAF mutation in metastasized papillary thyroid cancer in lymph nodes. J Clin Endocrinol Metab (2005) 1.04
Frequent mutations and amplifications of the PIK3CA gene in pituitary tumors. Endocr Relat Cancer (2008) 1.04
The Akt inhibitor MK2206 synergizes, but perifosine antagonizes, the BRAF(V600E) inhibitor PLX4032 and the MEK1/2 inhibitor AZD6244 in the inhibition of thyroid cancer cells. J Clin Endocrinol Metab (2011) 1.04
IQGAP1 plays an important role in the invasiveness of thyroid cancer. Clin Cancer Res (2010) 1.03
BRAF V600E mutation and papillary thyroid cancer. JAMA (2013) 1.03
Mutations in critical domains confer the human mTOR gene strong tumorigenicity. J Biol Chem (2013) 1.01
Frequent gene amplification predicts poor prognosis in gastric cancer. Int J Mol Sci (2012) 1.00
Uncommon GNAQ, MMP8, AKT3, EGFR, and PIK3R1 mutations in thyroid cancers. Endocr Pathol (2011) 0.99
Effect of Fgd1 on cortactin in Arp2/3 complex-mediated actin assembly. Biochemistry (2004) 0.98
Association of TERT promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. J Clin Endocrinol Metab (2015) 0.98
BRAF mutation in papillary thyroid microcarcinoma: the promise of better risk management. Ann Surg Oncol (2009) 0.98
Decreased 5-hydroxymethylcytosine (5-hmC) is an independent poor prognostic factor in gastric cancer patients. J Biomed Nanotechnol (2013) 0.97
Genetic-targeted therapy of thyroid cancer: a real promise. Thyroid (2009) 0.97
Histone deacetylation of NIS promoter underlies BRAF V600E-promoted NIS silencing in thyroid cancer. Endocr Relat Cancer (2014) 0.96
BRAFV600E mutation and papillary thyroid cancer: chicken or egg? J Clin Endocrinol Metab (2012) 0.95
Quantitative analysis of promoter hypermethylation in multiple genes in osteosarcoma. Cancer (2006) 0.94
Impact of lymph node metastases identified on central neck dissection (CND) on the recurrence of papillary thyroid cancer: potential role of BRAFV600E mutation in defining CND. Endocr Relat Cancer (2013) 0.94
Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin Chim Acta (2012) 0.94
A microarray to analyze methylation patterns of p16(Ink4a) gene 5'-CpG islands. Clin Biochem (2003) 0.92
TET1 exerts its tumor suppressor function by interacting with p53-EZH2 pathway in gastric cancer. J Biomed Nanotechnol (2014) 0.92
Association of promoter methylation with histologic type and pleural indentation in non-small cell lung cancer (NSCLC). Diagn Pathol (2011) 0.91
Induction of murine neonatal tolerance against Graves' disease using recombinant adenovirus expressing the TSH receptor A-subunit. Endocrinology (2011) 0.91
DKK3 is a potential tumor suppressor gene in papillary thyroid carcinoma. Endocr Relat Cancer (2013) 0.91
Novel variants related to TT virus distributed widely in China. J Med Virol (2002) 0.90
Hypermethylation of the DNA mismatch repair gene hMLH1 and its association with lymph node metastasis and T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer (2008) 0.90
Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway. BMC Cancer (2013) 0.89
TERT promoter mutations predict worse survival in laryngeal cancer patients. Int J Cancer (2014) 0.89